Ozempic and vision changes: what the label says, and what regulators added

Three different eye issues people mix up

Search results about "Ozempic and vision" lump together three different things. They have different causes, different odds and different next steps.

Knowing which one you're dealing with makes the rest of this guide easier to follow.

What the U.S. label says

The FDA-approved prescribing information for Ozempic (revised May 2026, the version we checked on October 31, 2026) lists diabetic retinopathy complications under Warnings and Precautions.

The label describes a 2-year trial in people with type 2 diabetes and high cardiovascular risk. Diabetic retinopathy complications occurred in 3.0% of people on Ozempic and 1.8% on placebo. The gap was bigger in people who already had retinopathy (8.2% versus 5.2%) than in people without it (0.7% versus 0.4%).

The label explains that rapid improvement in blood sugar control has been linked to a temporary worsening of diabetic retinopathy. It says people with a history of retinopathy should be monitored, and the patient Medication Guide tells people to tell their healthcare provider about changes in vision during treatment.

The U.S. label version we checked doesn't list NAION. That's where European and UK regulators have gone further.

What NAION is

NAION stands for non-arteritic anterior ischemic optic neuropathy. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) describes it as an extremely rare event caused by reduced blood flow to the front part of the optic nerve. It typically causes sudden, painless vision loss in one eye. People who've had it describe blurring or cloudiness.

The AAO says NAION affects about 2.3 to 10.2 people per 100,000 each year in general. It also lists other known risk factors: low blood pressure overnight, untreated sleep apnea and a very small optic nerve cup. People with diabetes are already at higher risk, whatever medicine they take.

Side effects are easier to spot when you're paying attention to how you feel day to day. Olive is a health companion that checks in with you every day, looks at what you eat, and helps you build small habits that actually hold. It doesn't diagnose or treat anything, so any change in your eyesight still goes straight to a doctor.

What regulators and researchers found

The study that raised the question. A 2024 study in JAMA Ophthalmology looked back at records from a neuro-ophthalmology practice at one academic institution. Among people prescribed semaglutide, NAION was more common than in matched groups on other medicines, both in people with type 2 diabetes and in people with overweight or obesity. The authors were clear that it was an observational study, so it couldn't show cause and effect.

Europe's review. In June 2025, the EMA's safety committee (PRAC) reviewed the data and concluded NAION is a very rare side effect of semaglutide medicines, including Ozempic, Rybelsus and Wegovy. It said studies suggest about a two-fold higher risk in people with type 2 diabetes taking semaglutide, which works out to roughly one extra case per 10,000 person-years. The EMA asked for product information to be updated.

The UK update. On 5 February 2026, the MHRA updated its guidance for prescribers and patients. It called the potential risk extremely small but said people should know the symptoms.

The eye doctors' view. In a September 2026 news release, the AAO said pooled studies suggest about a two-fold relative risk. Because NAION is uncommon to begin with, that means only a small absolute increase in cases. The AAO also noted that a large U.S. Military Health System study of about 1.2 million people didn't find an increased risk. Its conclusion: there's a possible association, but causation hasn't been established.

Where the advice differs: stopping the medicine

This is the one point where the sources don't fully agree, so it's worth reading carefully.

The EMA recommends stopping semaglutide if NAION is confirmed.

The AAO and the North American Neuro-Ophthalmology Society don't support a blanket rule. They say that for people with severe obesity, hard-to-control diabetes or heart disease, abruptly stopping the drug can be riskier than a rare eye event. They call for a shared decision with your care team instead.

Both positions share one point: this isn't a decision to make alone. Don't stop or change any prescribed medicine without talking to the clinician who prescribed it.

Symptoms that need urgent care

The MHRA says anyone taking semaglutide who notices a sudden change in eyesight, or eyesight that gets worse very quickly in one or both eyes, should get urgent care (in the UK, eye casualty or A&E). The EMA says to contact a doctor without delay. In the U.S., that means an emergency room or a same-day visit with an eye doctor.

Get urgent care for:

• Sudden vision loss, especially in one eye, even if it doesn't hurt
• A dark, blurry or cloudy area in part of your vision that appears suddenly
• Eyesight that worsens quickly over hours or days

Bring up these at your next appointment, or sooner if they worry you:

• Blurry vision that started when you began treatment and isn't improving after a few months
• Any vision change if you have diabetes, especially with known retinopathy

Should you get an eye exam before starting?

The AAO doesn't recommend routine eye exams just to check NAION risk before starting a GLP-1 medicine, because current evidence doesn't support it. But if you have diabetes, keep your regular diabetic eye exams. If you've already had NAION in one eye, the AAO says to talk with your doctor about the risk to the other eye before starting.

It also helps to tell your eye doctor about every medicine you take. The AAO's March 2026 article says to get your eyes checked regularly so changes can be tracked.

Questions to ask your prescriber

• Do I have any NAION risk factors, like sleep apnea or low blood pressure at night?
• I have diabetes. When should my next diabetic eye exam be?
• If my vision changes, who do I call first?
• What would we do if an eye problem were confirmed?

If nausea or other stomach side effects are also part of your week, our guide on what to eat when GLP-1 nausea hits can help. We also cover nutrient gaps on GLP-1s, getting enough protein and the Wegovy pill versus the injection.

This guide is general information, not medical advice. Don't stop or change a prescribed medicine on your own, and get urgent care for sudden vision loss.

Keep track while you're on treatment

Noticing changes early is easier when your daily routine is steady. Olive checks in with you every day and notices what's keeping your body stuck.

If steady habits haven't moved stubborn weight, Olive's Protocol is one option to look into. Prescriptions are only written after a medical consultation with a licensed provider. Not everyone qualifies.

See how Olive works →